HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Mear, J.-Y. Articles by Agid, Y. Search for Related Content PubMed PubMed Citation Articles by Mear, J.-Y. Articles by Agid, Y.

Pergolide in the treatment of Parkinson's disease

From Clinique de Neurologie et Neuropsychologie (Drs. Mear, de Smet, Lhermitte, and Agid), Paris, and Clinique de Neurologie (Drs. Barroche and Weher), Nancy, France.

Pergolide, a long-acting central dopamine agonist, was used as monotherapy in 16 parkinsonian patients. A mean daily dose of 6.3 mg resulted in 73% improvement of parkinsonian disability. Clinical improvement after acute administration of one dose of pergolide was similar to that observed after levodopa plus a peripheral decarboxylase inhibitor but at a dose 100 times lower (2.2 mg and 200 mg, respectively). The effect lasted twice as long (51/2 hours and 21/4 hours, respectively).

Address correspondence and reprint requests to Dr. Agid, Hôpital de la Salpêtriére, 47 boulevard de I'Hôpital, 75634 Paris, France.

Accepted for publication November 18, 1983.